Downregulation of microRNA‑605 indicates poor prognosis and promotes the progression of osteosarcoma

Yi,Xiuling; Liu,Chunlei

doi:10.3892/ol.2020.12233

Downregulation of microRNA‑605 indicates poor prognosis and promotes the progression of osteosarcoma

Authors:
- Xiuling Yi
- Chunlei Liu
View Affiliations

Affiliations: Department of Spinal Surgery, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China
Published online on: October 19, 2020 https://doi.org/10.3892/ol.2020.12233
Article Number: 370
Copyright: © Yi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma (OS) is a type of primary bone tumor, which is one of the leading causes of cancer‑related death. MicroRNA (miR)‑605 has been demonstrated to act as a prognostic biomarker and therapeutic target in various cancers, such as breast cancer and non‑small cell lung cancer, but its function in OS remains unclear. The aim of the present study was to investigate the prognostic value of miR‑605 in patients with OS by evaluating its expression levels and to explore the biological function of miR‑605 in OS progression. For this purpose, tumor tissues and adjacent normal tissues were collected from OS patients, and the expression of miR‑605 in the collected tissues and OS MG63, U2OS, HOS, and SAOS‑2 cell lines was detected by quantitative real‑time PCR. The prognostic value of miR‑605 was evaluated by Kaplan‑Meier survival curves and Cox regression analysis. The effects of miR‑605 on OS cell proliferation, migration and invasion were analyzed by the CCK‑8 and transwell assays, respectively. The results of the present study revealed that miR‑605 was significantly downregulated in OS tissues compared with adjacent normal tissues, which was associated with the clinical stage and distant metastasis of patients. Additionally, the downregulation of miR‑605 predicted the poor prognosis of patients with OS and served as an independent prognostic indicator. The downregulation of miR‑605 enhanced cell proliferation, migration, and invasion of OS cells, which suggested that miR‑605 may be involved in the progression of OS. The findings of the present study provide a new therapeutic target for the treatment of patients with OS.

View Figures

View References

1	Selvarajah S, Yoshimoto M, Ludkovski O, Park PC, Bayani J, Thorner P, Maire G, Squire JA and Zielenska M: Genomic signatures of chromosomal instability and osteosarcoma progression detected by high resolution array CGH and interphase FISH. Cytogenet Genome Res. 122:5–15. 2008. View Article : Google Scholar : PubMed/NCBI
2	Selvarajah S, Yoshimoto M, Maire G, Paderova J, Bayani J, Squire JA and Zielenska M: Identification of cryptic microaberrations in osteosarcoma by high-definition oligonucleotide array comparative genomic hybridization. Cancer Genet Cytogenet. 179:52–61. 2007. View Article : Google Scholar : PubMed/NCBI
3	Wang J, Liu S, Shi J, Li J, Wang S, Liu H, Zhao S, Duan K, Pan X and Yi Z: The role of miRNA in the diagnosis, prognosis, and treatment of osteosarcoma. Cancer Biother Radiopharm. 34:605–613. 2019. View Article : Google Scholar : PubMed/NCBI
4	Anderson ME: Update on survival in osteosarcoma. Orthop Clin North Am. 47:283–292. 2016. View Article : Google Scholar : PubMed/NCBI
5	Song K, Song J, Lin K, Chen F, Ma X, Jiang J and Li F: Survival analysis of patients with metastatic osteosarcoma: A Surveillance, Epidemiology, and End Results population-based study. Int Orthop. 43:1983–1991. 2019. View Article : Google Scholar : PubMed/NCBI
6	Ouyang L, Liu P, Yang S, Ye S, Xu W and Liu X: A three-plasma miRNA signature serves as novel biomarkers for osteosarcoma. Med Oncol. 30:3402013. View Article : Google Scholar : PubMed/NCBI
7	Zhang J, Yan YG, Wang C, Zhang SJ, Yu XH and Wang WJ: MicroRNAs in osteosarcoma. Clin Chim Acta. 444:9–17. 2015. View Article : Google Scholar : PubMed/NCBI
8	Hesse E and Taipaleenmäki H: MicroRNAs in bone metastasis. Curr Osteoporos Rep. 17:122–128. 2019. View Article : Google Scholar : PubMed/NCBI
9	Qu K, Wang Z, Lin XL, Zhang K, He XL and Zhang H: MicroRNAs: Key regulators of endothelial progenitor cell functions. Clin Chim Acta. 448:65–73. 2015. View Article : Google Scholar : PubMed/NCBI
10	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
11	Hironaka-Mitsuhashi A, Otsuka K, Gailhouste L, Sanchez Calle A, Kumazaki M, Yamamoto Y, Fujiwara Y and Ochiya T: miR-1285-5p/TMEM194A axis affects cell proliferation in breast cancer. Cancer Sci. 111:395–405. 2020. View Article : Google Scholar : PubMed/NCBI
12	Qin S, Ai F, Ji WF, Rao W, Zhang HC and Yao WJ: miR-19a promotes cell growth and tumorigenesis through targeting SOCS1 in gastric cancer. Asian Pac J Cancer Prev. 14:835–840. 2013. View Article : Google Scholar : PubMed/NCBI
13	Chen J and Chen Z: Downregulation of miR-19a inhibits the proliferation and promotes the apoptosis of osteosarcoma cells by regulating the JAK2/STAT3 pathway. Oncol Lett. 20:1732020. View Article : Google Scholar : PubMed/NCBI
14	Sun L, Wang L, Luan S, Jiang Y and Wang Q: miR-429 inhibits osteosarcoma progression by targeting HOXA9 through suppressing Wnt/β-catenin signaling pathway. Oncol Lett. 20:2447–2455. 2020. View Article : Google Scholar : PubMed/NCBI
15	Yao J, Tan W, Wu W, Ye R, Li Y and Chen Y: Effects of miR-432 and miR-548c-3p on the proliferation and invasion of osteosarcoma cells. J BUON. 25:1562–1568. 2020.PubMed/NCBI
16	Zhou L, Lu Y, Liu JS, Long SZ, Liu HL, Zhang J and Zhang T: The role of miR-21/RECK in the inhibition of osteosarcoma by curcumin. Mol Cell Probes. 51:1015342020. View Article : Google Scholar : PubMed/NCBI
17	Wang Y, Shi S, Zhang Q, Dong H and Zhang J: MicroRNA-206 upregulation relieves circTCF25-induced osteosarcoma cell proliferation and migration. J Cell Physiol jcp.29570. 2020.
18	Liao Y, Cao L, Wang F and Pang R: miR-605-5p promotes invasion and proliferation by targeting TNFAIP3 in non-small-cell lung cancer. J Cell Biochem. 121:779–787. 2020. View Article : Google Scholar : PubMed/NCBI
19	Zhou YJ, Yang HQ, Xia W, Cui L, Xu RF, Lu H, Xue Z, Zhang B, Tian ZN, Cao YJ, et al: Down-regulation of miR-605 promotes the proliferation and invasion of prostate cancer cells by up-regulating EN2. Life Sci. 190:7–14. 2017. View Article : Google Scholar : PubMed/NCBI
20	Zhang C, Wan J, Long F, Liu Q and He H: Identification and validation of microRNAs and their targets expressed in osteosarcoma. Oncol Lett. 18:5628–5636. 2019.PubMed/NCBI
21	Cates JM: Comparison of the AJCC, MSTS, and modified spanier systems for clinical and pathologic staging of osteosarcoma. Am J Surg Pathol. 41:405–413. 2017. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Jia G, Wang Y, Yu Y, Li Z and Wang X: Long non coding RNA NR2F1 AS1 facilitates the osteosarcoma cell malignant phenotype via the miR 485 5p/miR 218 5p/BIRC5 axis. Oncol Rep. 44:1583–1595. 2020.PubMed/NCBI
24	Fan H, Liu T, Tian H and Zhang S: TUSC8 inhibits the development of osteosarcoma by sponging miR 197 3p and targeting EHD2. Int J Mol Med. 46:1311–1320. 2020.PubMed/NCBI
25	Wang L, Jiang J, Sun G, Zhang P and Li Y: Effects of lncRNA TUSC7 on the malignant biological behavior of osteosarcoma cells via regulation of miR-375. Oncol Lett. 20:1332020. View Article : Google Scholar : PubMed/NCBI
26	Feliciano A, Garcia-Mayea Y, Jubierre L, Mir C, Hummel M, Castellvi J, Hernández-Losa J, Paciucci R, Sansano I, Sun Y, et al: miR-99a reveals two novel oncogenic proteins E2F2 and EMR2 and represses stemness in lung cancer. Cell Death Dis. 8:e31412017. View Article : Google Scholar : PubMed/NCBI
27	Zuberi M, Khan I, Mir R, Gandhi G, Ray PC and Saxena A: Utility of serum miR-125b as a diagnostic and prognostic indicator and its alliance with a panel of tumor suppressor genes in epithelial ovarian cancer. PLoS One. 11:e01539022016. View Article : Google Scholar : PubMed/NCBI
28	Mousa H, Yuan M, Zhang X, Li X, Shopit A, Almoiliqy M, Alshwmi M, Al-Dherasi A, Xu Y and Zuo Y: MicroRNA-4316 inhibits gastric cancer proliferation and migration via directly targeting VEGF-A. Cancer Cell Int. 20:622020. View Article : Google Scholar : PubMed/NCBI
29	Huang D, Sun W, Zhou Y, Li P, Chen F, Chen H, Xia D, Xu E, Lai M, Wu Y, et al: Mutations of key driver genes in colorectal cancer progression and metastasis. Cancer Metastasis Rev. 37:173–187. 2018. View Article : Google Scholar : PubMed/NCBI
30	Wei F, Wang M, Li Z, Wang Y and Zhou Y: miR 593 inhibits proliferation and invasion and promotes apoptosis in non small cell lung cancer cells by targeting SLUG associated signaling pathways. Mol Med Rep. 20:5172–5182. 2019.PubMed/NCBI
31	Sun R, Shen J, Gao Y, Zhou Y, Yu Z, Hornicek F, Kan Q and Duan Z: Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential. Oncotarget. 7:38333–38346. 2016. View Article : Google Scholar : PubMed/NCBI
32	Zhang W, Wei L, Sheng W, Kang B, Wang D and Zeng H: miR-1225-5p Functions as a tumor suppressor in osteosarcoma by targeting Sox9. DNA Cell Biol. 39:78–91. 2020. View Article : Google Scholar : PubMed/NCBI
33	Wang Y, Huang H and Li Y: Knocking down miR-384 promotes growth and metastasis of osteosarcoma MG63 cells by targeting SLBP. Artif Cells Nanomed Biotechnol. 47:1458–1465. 2019. View Article : Google Scholar : PubMed/NCBI
34	Li J, Tian F, Li D, Chen J, Jiang P, Zheng S, Li X and Wang S: miR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression. FEBS Lett. 588:3491–3500. 2014. View Article : Google Scholar : PubMed/NCBI
35	Chen L and Cao Y, Rong D, Wang Y and Cao Y: MicroRNA-605 functions as a tumor suppressor by targeting INPP4B in melanoma. Oncol Rep. 38:1276–1286. 2017. View Article : Google Scholar : PubMed/NCBI
36	Danesh H, Hashemi M, Bizhani F, Hashemi SM and Bahari G: Association study of miR-100, miR-124-1, miR-218-2, miR-301b, miR-605, and miR-4293 polymorphisms and the risk of breast cancer in a sample of Iranian population. Gene. 647:73–78. 2018. View Article : Google Scholar : PubMed/NCBI
37	Pan MZ, Song YL and Gao F: miR-605-3p inhibits malignant progression of prostate cancer by up-regulating EZH2. Eur Rev Med Pharmacol Sci. 23:8795–8805. 2019.PubMed/NCBI
38	Zhou W and Li R: MicroRNA-605 inhibits the oncogenicity of non-small-cell lung cancer by directly targeting Forkhead Box P1. OncoTargets Ther. 12:3765–3777. 2019. View Article : Google Scholar
39	Qiu C, Li S, Sun D and Yang S: lncRNA PVT1 accelerates progression of non-small cell lung cancer via targeting miRNA-526b/EZH2 regulatory loop. Oncol Lett. 19:1267–1272. 2020.PubMed/NCBI
40	Chen Z, Du Y, Liu X, Chen H, Weng X, Guo J, Wang M, Wang X and Wang L: EZH2 inhibition suppresses bladder cancer cell growth and metastasis via the JAK2/STAT3 signaling pathway. Oncol Lett. 18:907–915. 2019.PubMed/NCBI